Granted Patent B2

US 12,569,479 · App. 18/636,240 · Granted Mar 10, 2026

Inventor: Herriot Tabuteau (New York, NY)

Assignee: ANTECIP BIOVENTURES II LLC

A61K31/485A61K31/135A61K9/0053

Abstract

Claims (21)

1 . A method of treating depression comprising: orally administering a dosage form daily to a human being suffering from depression; wherein the dosage form comprises dextromethorphan or a pharmaceutically acceptable salt thereof, and escitalopram or a pharmaceutically acceptable salt thereof; wherein the dextromethorphan and the escitalopram are the only therapeutically active agents in the dosage form; and wherein the human being is an extensive metabolizer of dextromethorphan.

2 . The method of claim 1 , wherein the dosage form is orally administered for at least 8 consecutive days.

3 . The method of claim 1 , wherein the depression is major depressive disorder.

4 . The method of claim 1 , wherein the depression is treatment resistant depression.

5 . The method of claim 1 , wherein the dosage form comprises about 5 mg to about 20 mg of the escitalopram.

6 . The method of claim 1 , wherein the dosage form is orally administered for at least 14 consecutive days.

7 . The method of claim 1 , wherein the dosage form provides immediate release of dextromethorphan or a pharmaceutically acceptable salt thereof.

8 . The method of claim 1 , wherein the dosage form provides sustained release of the escitalopram.

9 . The method of claim 1 , wherein the dosage form contains about 20 mg to about 50 mg of dextromethorphan or a pharmaceutically acceptable salt thereof.

10 . The method of claim 1 , wherein the dosage form contains about 30 mg to about 60 mg of dextromethorphan or a pharmaceutically acceptable salt thereof.

11 . The method of claim 1 , wherein the dosage form contains about 40 mg to about 50 mg of dextromethorphan or a pharmaceutically acceptable salt thereof.

12 . The method of claim 1 , wherein the dosage form contains about 50 mg to about 70 mg of dextromethorphan or a pharmaceutically acceptable salt thereof.

13 . The method of claim 1 , wherein the dosage form contains about 70 mg to about 100 mg of dextromethorphan or a pharmaceutically acceptable salt thereof.

14 . The method of claim 1 , wherein the dosage form contains about 45 mg of a dextromethorphan salt.

15 . The method of claim 1 , wherein the dextromethorphan comprises a deuterium-modified dextromethorphan or a pharmaceutically acceptable salt thereof.

16 . The method of claim 1 , wherein the dosage form is a capsule, a tablet, or a solution.

17 . The method of claim 1 , wherein a dextromethorphan plasma level is increased as compared to administering the same amount of dextromethorphan or a pharmaceutically acceptable salt thereof alone.

18 . The method of claim 1 , wherein the human being is converted to a poor metabolizer of dextromethorphan.

19 . The method of claim 1 , wherein the dosage form further comprises a pharmaceutically acceptable excipient.

20 . The method of claim 1 , wherein the elimination half-life of dextromethorphan or a pharmaceutically acceptable salt thereof increases upon orally administering the dosage form.

21 . The method of claim 14 , wherein the dextromethorphan salt is dextromethorphan hydrobromide.

Assignments (1)

Continuity (19)

References Cited (400)